Company
Ambagon Therapeutics
The 14-3-3 Molecular Glue Company
Also known as Ambagon, Ambagon Therapeutics B.V.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Ambagon Therapeutics B.V.
- ambagontx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
With founders who are global leaders in the structural biology of 14-3-3 proteins and their role in a wide range of protein-protein interactions, our team is developing a new class of medicines that can modulate previously undruggable targets and influence currently accessible ones in new ways.
Funding snapshot
- Total raised
- $57.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $5M2025-01-24
Funding rounds
- Round, 2025
- $5M2025-01-24, SEC form D sold, 4 investors
- Round, 2022
- $45M2022-01-05, SEC form D sold, 9 investors
- Round, 2020
- $7.2M2020-07-17, SEC form D sold, 8 investors
Loading relationship preview